1. Home
  2. CATX

as 04-18-2025 1:33pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medical/Dental Instruments

Nasdaq

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Founded: 1983 Country:
United States
United States
Employees: N/A City: SEATTLE
Market Cap: 133.3M IPO Year: N/A
Target Price: $13.89 AVG Volume (30 days): 950.5K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.23 EPS Growth: N/A
52 Week Low/High: $1.60 - $19.10 Next Earning Date: 05-12-2025
Revenue: $1,454,000 Revenue Growth: 1.40%
Revenue Growth (this year): -48.34% Revenue Growth (next year): 1.15%

CATX Daily Stock ML Predictions

Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Woods Lori A CATX Director Mar 31 '25 Buy $2.13 23,475 $49,999.40 183,460
Graham Juan CATX Chief Financial Officer Mar 28 '25 Buy $2.25 33,333 $74,945.92 35,354
Williamson Robert F III CATX Director Mar 28 '25 Buy $2.21 60,337 $132,151.09 70,837
Spoor Johan M. CATX Chief Executive Officer Mar 28 '25 Buy $2.23 26,676 $59,672.62 59,383

Share on Social Networks: